Dataset Information


Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.

ABSTRACT: Heavy-drinking smokers constitute a sizeable and hard-to-treat subgroup of smokers, for whom tailored smoking cessation therapies are not yet available.The present study used a double-blind, randomized, 2?×?2 medication design, testing varenicline alone (VAR; 1 mg twice daily), low dose naltrexone alone (L-NTX; 25 mg once daily), varenicline plus naltrexone, and placebo for effects on cigarette craving and subjective response to alcohol and cigarettes in a sample (n?=?130) of heavy-drinking daily smokers (?10 cigarettes/day).All participants were tested after a 9-day titration period designed to reach a steady state on the target medication. Testing was completed at 12 h of nicotine abstinence, after consuming a standard dose of alcohol (target breath alcohol concentration?=?0.06 g/dl) and after smoking the first cigarette of the day.The combination of VAR?+?L-NTX was superior to placebo, and at times superior to monotherapy, in attenuating cigarette craving, cigarette and alcohol "high," and in reducing ad-lib consumption of both cigarettes and alcohol during the 9-day medication titration period.These preliminary findings indicate that clinical studies of the combination of VAR?+?L-NTX for heavy drinkers trying to quit smoking are warranted and may ultimately improve clinical care for this sizeable and treatment-resistant subgroup of smokers.

PROVIDER: S-EPMC4161630 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC5970035 | BioStudies
| S-EPMC5880727 | BioStudies
| S-EPMC7437557 | BioStudies
| S-EPMC6196126 | BioStudies
| S-EPMC6450273 | BioStudies
| S-EPMC5549617 | BioStudies
| S-EPMC3438402 | BioStudies
| S-EPMC7889999 | BioStudies
| S-EPMC5017904 | BioStudies
| S-EPMC6901445 | BioStudies